PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

Completed · Not applicable

Conditions studied: Coronary Artery Disease

In brief

The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents. This prospective, global, multi-center, randomized 2:1, single blind study will enroll up to 1632 subjects at up to 130 investigational sites in North America, Japan, and Europe. Subjects will have clinical follow-up in-hospital and at 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years.

Key facts

Study ID: NCT03168776
Run by: Sino Medical Sciences Technology Inc.
People needed: 1629
Starts: 2017-10-13
Expected to finish: 2024-10-01
Last updated by the study team: 2026-01-27

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

The patient is a male or non-pregnant female ≥20 years of age.
The patient has symptomatic ischemic heart disease, including chronic stable angina (and/or objective evidence of myocardial ischemia on functional study or invasive fractional flow reserve [FFR] measurement) or acute coronary syndromes (UA or NSTEMI), that requires elective or urgent percutaneous coronary intervention (PCI).
The patient is an acceptable candidate for percutaneous coronary intervention (PCI) with drug-eluting stents, and for emergent coronary bypass graft (CABG) surgery.
The patient is willing to comply with specified follow-up evaluations.
The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

You may not qualify if…

Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test.
Patients with a history of bleeding diathesis or coagulopathy, contraindications to anti-platelet and/or anticoagulant therapy, or who will refuse transfusion.
Patients who are receiving or will require chronic anticoagulation therapy for any reason.
Known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, ADP receptor antagonists (clopidogrel, prasugrel, ticagrelor, ticlopidine), cobalt chromium, 316L stainless steel or platinum, sirolimus or its analogues, and/or contrast sensitivity that cannot be adequately pre-medicated.
ST-segment elevation myocardial infarction (STEMI) at index presentation or within 7 days prior to randomization.
Known LVEF <30% or cardiogenic shock requiring pressors or mechanical circulatory assistance (e.g., intra-aortic balloon pump, left ventricular assist device, other temporary cardiac support blood pump).
Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation or Cockcroft-Gault formula) or dialysis at the time of screening.
Target vessel percutaneous coronary intervention with stent placement in the previous 3 months.
Planned elective surgery that would require discontinuation of DAPT within 6 months of the index procedure.
Past or pending heart or any other organ transplant, or on the waiting list for any organ transplant.
Patients who are receiving immunosuppressant therapy, or who have known immunosuppressive or severe autoimmune disease that will require chronic immunosuppressive therapy. NOTE: Corticosteroid use is permitted.
Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound data interpretation, or is associated with a life expectancy of less than 1 year.
Current participation in another investigational drug or device study.

Where it is running

Dignity Health - Mercy Gilbert Medical Center / Chandler Regional Medical Center — Gilbert, Arizona, United States
Smidt Heart Institute Cedars-Sinai Maedical Center — Los Angeles, California, United States
Yale University — New Haven, Connecticut, United States
Medstar Washington HWospital Center — Washington D.C., District of Columbia, United States
Bethesda Hospital East/Daniel Heart and Vascular Center — Boynton Beach, Florida, United States
Clearwater Cardiovascular Consultants — Clearwater, Florida, United States
MediQuest Research Group Inc. — Ocala, Florida, United States
Cardiovascular Institute of Northwest Florida — Panama City, Florida, United States
Florida Hospital Tampa — Tampa, Florida, United States
Emory University Hospital — Atlanta, Georgia, United States
Krannert Institute of Cardiology — Indianapolis, Indiana, United States
St. Vincent's Medical Group — Indianapolis, Indiana, United States
Iowa Heart Center — Des Moines, Iowa, United States
Norton Brownsboro Hospital — Louisville, Kentucky, United States
Medstar Union Memorial Hospital — Baltimore, Maryland, United States
Northern Michigan Hospital d.b.a. McLaren Northern Michigan — Petoskey, Michigan, United States
William Beaumont Hospital — Royal Oak, Michigan, United States
Michigan Heart — Ypsilanti, Michigan, United States
Essential Health — Duluth, Minnesota, United States
North MS Medical Center — Tupelo, Mississippi, United States
CHI Health Research Center — Omaha, Nebraska, United States
Cardiovascular Associates of Delaware Valley — Haddon Heights, New Jersey, United States
Columbia University Medical Center / New York Presbyterian Hospital — New York, New York, United States
NC Heart and Vascular Research — Raleigh, North Carolina, United States
Cardiology, PC — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.